For the most part, these have been secondary outcomes, although complementary dedicated HF and renal outcomes studies that included patients with and without T2D have recently been published for SGLT2 inhibitors [18, 36, 68, 69, 71, 72], while large-scale real-world outcomes studies have provided further insights [73–82]. Here, SLC5A2 is linked to type 2 diabetes mellitus.